Retatrutide vs 5-Amino-1MQ
Retatrutide and 5-Amino-1MQ are both studied in metabolic research, but they sit at opposite ends of nearly every axis that matters — administration route, molecular class, and how much human trial evidence exists for each.
At a Glance
| Retatrutide | 5-Amino-1MQ | |
|---|---|---|
| Category | Weight Loss & Metabolic | Weight Loss & Metabolic |
| Molecular class | Synthetic triple agonist peptide (GIP/GLP-1/glucagon receptors) | Small molecule NNMT inhibitor — not a peptide |
| Origin | Eli Lilly incretin-biology group; preclinical paper Coskun et al., Cell Metabolism, Sept 2022 | 2014 genetic study (Kraus et al., Nature); compound introduced 2018 (Neelakantan et al.) |
| Studied via | Subcutaneous injection | Oral administration |
| Primary mechanism | Simultaneous activation of the GIP, GLP-1, and glucagon receptors | Inhibits NNMT, raising cellular NAD⁺/SAM levels |
| Primary research focus | Body weight loss, energy expenditure, glycemic control | Body weight, white adipose mass (mouse models) |
| Human trial data | Phase 3 (TRIUMPH program) — up to 28.3% weight loss at 80 weeks (TRIUMPH-1); not yet approved | None — preclinical/animal only |
How They Differ
Retatrutide is a deliberately engineered injectable peptide from Eli Lilly's incretin-biology research group — the same program responsible for tirzepatide. It's designed to activate three separate hormone receptors (GIP, GLP-1, and glucagon) simultaneously, and it's now deep into human Phase 3 trials with strong published efficacy data. See its full discovery history, or how it compares to semaglutide and tirzepatide.
5-Amino-1MQ isn't a peptide at all, despite being sold alongside peptides in the same research category. Its research lineage starts with a 2014 genetic knockdown study that established NNMT (nicotinamide N-methyltransferase) as an obesity-relevant target in mice, followed by a 2018 pharmacology study that introduced 5-Amino-1MQ itself as a small-molecule inhibitor of that enzyme. Unlike Retatrutide, it's studied via oral administration, and all available evidence remains confined to mouse studies. See its full discovery history, or how it compares to MOTS-c.
Clinical Trial Data
Retatrutide: The Phase 3 TRIUMPH-1 trial (2,339 adults with obesity or overweight and at least one weight-related condition, without type 2 diabetes) reported a mean weight loss of 28.3% at the 12mg dose over 80 weeks, with 45.3% of participants losing at least 30% of body weight — a threshold historically associated with bariatric surgery. A study extension in participants with baseline BMI ≥35 reached an average of 30.3% weight loss at 104 weeks. All three doses tested (4mg, 9mg, 12mg) met their primary and key secondary endpoints against placebo. Full peer-reviewed results are still pending publication, following the precedent set by Retatrutide's Phase 2 obesity data published in the New England Journal of Medicine in 2023. Retatrutide remains investigational and has not been approved by the FDA or any other regulator.
5-Amino-1MQ: All available data is preclinical. A 2014 genetic knockdown study (Kraus et al., Nature) established NNMT as an obesity-relevant target in mice, and a 2018 pharmacology study (Neelakantan et al., Biochemical Pharmacology, University of Texas Medical Branch) introduced 5-Amino-1MQ itself, showing it reduced body weight and white adipose mass in diet-induced obese mice without affecting food intake or lean mass. No human clinical trials have been conducted.
Why They're Often Compared
Retatrutide and 5-Amino-1MQ are two of KYIN's three Weight Loss & Metabolic compounds, and together they illustrate two of the most divergent research paths in the category: a late-stage, well-capitalized injectable receptor agonist following the well-trodden route of the blockbuster GLP-1 drug class, versus an early-stage oral small molecule with evidence still confined entirely to animal studies. Researchers weighing the two are often comparing not just mechanism, but administration route and how much human evidence currently exists to support each.
Retatrutide vs 5-Amino-1MQ questions
Why are Retatrutide and 5-Amino-1MQ often compared?
They're two of KYIN's three Weight Loss / Metabolic compounds, and they sit at opposite ends of both administration route (injectable vs. oral) and evidence maturity (Phase 3 human data vs. mouse-only data).
Is 5-Amino-1MQ actually a peptide?
No. Despite being sold alongside peptides in the same research category, 5-Amino-1MQ is a small molecule, not a peptide. It's studied as an inhibitor of the enzyme NNMT (nicotinamide N-methyltransferase), and unlike Retatrutide, it's studied via oral administration in the available literature.
Which has more human trial data, Retatrutide or 5-Amino-1MQ?
Retatrutide, by a wide margin — its Phase 3 TRIUMPH-1 trial reported up to 28.3% mean weight loss at 80 weeks in over 2,300 participants. 5-Amino-1MQ has no human clinical trial data at all; all available evidence comes from mouse studies.
Looking for specs and pricing?
View purity, available sizes, and pricing for both.